English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduLantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. (“Evergreen”), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Tag: Radiopharmaceutical
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
Promising Medical Isotope Made and Processed at Brookhaven Lab
Thanks to a recent upgrade to the medical isotope facilities at Brookhaven National Laboratory, actinium-225 (Ac-225), an isotope that shows great promise for treating cancer, can now be produced, purified, and shipped ready for use directly from the Lab. The first shipment left Brookhaven in mid-March.
Imaging technique may measure absorbed dose from radiation therapy
Abhinav Jha, at the McKelvey School of Engineering, wants to use novel imaging to better understand how people absorb radiation therapy. His team won a four-year $2.2 million National Institutes of Health (NIH) grant for the study, which aims to guide treatment decisions.